BACK TO CBER — Dr. Vinay Prasad has returned to the FDA’s Center for Biologics Evaluation and Research, leaving industry and ...

Entergy Louisiana asks regulators to fast-track a major power project for Meta’s Richland Parish data center amid cost ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

Vinay Prasad resumes leadership at the FDA’s CBER two weeks after he resigned amid cell and gene therapy controversy.

WASHINGTON, DC – Dr. Vinay Prasad has been reinstated to a senior position at the Food and Drug Administration, according to ...

The shares of biotech companies fell after news that ousted regulator Vinay Prasad is set to go back to the US Food and Drug Administration. Prasad had previously overruled his own scientific review ...

Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the U.S. Food and Drug ...

With a strong launch underway for a bladder cancer gene therapy, Ferring Pharmaceuticals is finding the kind of commercial ...

Vinay Prasad is once again head of the FDA’s Center for Biologics Evaluation and Research, after Laura Loomer led a campaign ...

Coinbase and MicroStrategy stocks rose as Bitcoin price surged. Shares of Sarepta, Nvidia and AMD were falling in early ...

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...

At 05:45 a.m. ET, Dow E-minis were up 98 points, or 0.22%, with 7,922 contracts changing hands, S&P 500 E-minis were up 6.25 ...